In the phase III HIMALAYA trial, a single priming dose of tremelimumab plus once-monthly durvalumab was associated with better overall survival compared with sorafenib as first-line treatment for patients with inoperable hepatocellular carcinoma.
In the phase III HIMALAYA trial, a single priming dose of tremelimumab plus once-monthly durvalumab was associated with better overall survival compared with sorafenib as first-line treatment for patients with inoperable hepatocellular carcinoma.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
